Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio’s DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company’s web site at www.inovio.com.
- 17 years ago
QualityStocks
Inovio Biomedical Corporation (AMEX: INO)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Advances Beacon Gold Mill Restart, Reports High-Grade Results From Swanson Deposit
LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) provided an update on ramp-up activities at…
-
QualityStocksNewsBreaks – Game On: Brera Holdings PLC’s (NASDAQ: BREA) MCO Strategy Draws Analyst Support
Brera Holdings (NASDAQ: BREA) is an Ireland-based international holding company focused on expanding its global portfolio…
-
QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug…